Dupilumab (Dupixent®), a monoclonal antibody to anti-IL4Rα, is approved for treating moderate-to-severe AD, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis [31]. This evidence concerns the gene IL4R and Alzheimer disease.